2025 Scrip Asia 100
Latest Updates And Considerations In Asia Pacific
China
China’s biopharma sector is pushing forward with significant innovations, particularly in oncology and biologics, though market pressures and regulatory hurdles continue to pose challenges for sustained growth.
Will US Clinical Study Diversity Guidance Cloud Chinese Firms’ Prospects For Going Global?
The latest FDA guidance will have profound impact to Chinese biotech sector at a time when going global and a US approval is vital to its very survival.
